OncoMatch/Clinical Trials/NCT05613023
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
Is NCT05613023 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies non-drug interventions for prostate cancer.
This study will compare the safety and efficacy of curative radiotherapy to the prostate and lymph glands given in 5 visits to that of prostate alone radiotherapy given in 5 visits, in men with high risk localised prostate cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Grade: Gleason 8-10ISUP grade group 4ISUP grade group 5 (Gleason/ISUP)
High risk localised prostate cancer as defined by * Gleason 8-10 (grade groups 4 and 5) and/or * Stage T3a/b or T4
Performance status
WHO 0–2
Demographics
Prior therapy
Cannot have received: active treatment for prostate cancer
Previous active treatment for prostate cancer
Cannot have received: chemotherapy
Exception: within 6 weeks of the start of radiotherapy
Patients who have had chemotherapy within 6 weeks of the start of radiotherapy.
Cannot have received: pelvic radiotherapy
prior pelvic radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05613023 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages